|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Appendix 1: Medical resource utilization cost (overall and consolidation phase)** | | | | |
|  | **Overall study** | | **Consolidation phase** | |
| **Category** | **PemCis**  **N=283** | **EtoCis**  **N=272** | **PemCis**  **N=230** | **EtoCis**  **N=204** |
| **Follow up, months, mean**±**SD** | **4.47±1.46** | **3.50±1.11** | 2.58±0.73 | 1.59±0.45 |
| **Total cost, $, mean±SD** | **51,313.90±33,166.11** | **22,425.24±26,087.53** | **27,614.28±18,684.41** | **6,502.07±8,752.18** |
| **Study treatment cost, $, mean±SD** | **31,203.67±11,217.62** | **2,957.81±900.48** | **19,052.51±5,747.81** | **1,447.03±470.20** |
| **Other costsa, $, mean±SD** | 20,110.22±32,883.10 | 19,467.43±26,141.99 | 8,561.77±18,705.07 | 5,055.05±8,751.18 |
| **Monthly other costsb, $, mean±SD** | **5,939.39±11,482.57** | **6,743.95±10,590.52** | **3,891.56±9,006.24** | **3,638.25±6,856.97** |
| **Adverse event–related costc, $, mean±SD** | 17,618.29±32,804.57 | 16,901.28±25,765.38 | 7,806.70±18,664.27 | 4,045.76±8,470.69 |
| **Hospitalization cost, $, mean±SD** | 16,071.19±31,775.90 | 14,395.61±24,578.96 | **6,924.14±17,870.17** | **2,524.46±7,158.77** |
| **Radiotherapy cost, $, mean±SD** | 485.86±108.03 | 480.54±94.25 | 0.00±0.00 | 0.00±0.00 |
| **Supportive care costd, $, mean±SD** | 45.27±238.88 | 45.87±212.73 | 37.04±219.98 | 31.22±173.61 |
| **Concomitant medication usage cost, $** | 3,158.12±3,615.92 | 4,238.32±5,242.10 | **1,384.79±2,731.71** | **2,319.85±3,741.74** |
| **Laboratory/evaluation/radiology visit cost, $, mean±SD** | **192.48±129.55** | **161.20±126.16** | **120.59±125.09** | **95.24±121.25** |
| **Blood products cost, $, mean±SD** | 157.31±373.15 | 145.89±325.66 | 95.21±239.88 | 84.27±204.48 |

EtoCis, etoposide, cisplatin, and concurrent thoracic radiation therapy, followed by consolidation with cytotoxic chemotherapy of choice; PemCis, pemetrexed, cisplatin, and concurrent thoracic radiation therapy followed by consolidation pemetrexed; SD, standard deviation.

Statistically significant differences are shown in bold text and are based on p - value (<0.05) determined by Wilcoxon rank sum test.

aInclude hospitalizations, radiotherapy, supportive care, concomitant medications, laboratory/evaluation/radiology visits, and blood products.

bCalculated by the total other costs divided by the difference in start and end dates for a period per 30.5 days.

cInclude concomitant medications, hospitalizations, and blood products associated with an adverse event and these costs may also appear in other categories.

dSupportive care comprised administrations for pulmonary function tests, administration of oxygen (intermittent or continuous), insertion of a gastric feeding tube, administration of intravenous fluid, esophageal dilation, and endoscopy.

Note: Study treatment cost includes hospital visits and other procedural costs associated with study drug administration. Overall study results include costs incurred during the concurrent phase and the consolidation phase. Costs incurred during the recovery phase or follow-up are not included in this analysis.